SG Americas Securities LLC Acquires Shares of 435,842 Embecta Corp. $EMBC

SG Americas Securities LLC bought a new position in Embecta Corp. (NASDAQ:EMBC) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 435,842 shares of the company’s stock, valued at approximately $5,178,000. SG Americas Securities LLC owned approximately 0.74% of Embecta as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Larson Financial Group LLC lifted its stake in shares of Embecta by 368.6% during the 3rd quarter. Larson Financial Group LLC now owns 2,001 shares of the company’s stock valued at $28,000 after buying an additional 1,574 shares in the last quarter. Wexford Capital LP purchased a new position in Embecta in the 3rd quarter valued at approximately $94,000. Tower Research Capital LLC TRC raised its holdings in Embecta by 542.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,371 shares of the company’s stock valued at $71,000 after acquiring an additional 6,224 shares during the period. iSAM Funds UK Ltd purchased a new stake in shares of Embecta during the third quarter worth $115,000. Finally, Neuberger Berman Group LLC purchased a new stake in shares of Embecta during the third quarter worth $143,000. Institutional investors own 93.83% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on EMBC shares. BTIG Research reiterated a “buy” rating and issued a $25.00 price target on shares of Embecta in a research report on Friday, February 6th. Wall Street Zen raised Embecta from a “buy” rating to a “strong-buy” rating in a report on Saturday, March 7th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Embecta in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, Embecta presently has a consensus rating of “Hold” and an average target price of $18.50.

Embecta Stock Performance

Shares of EMBC stock opened at $8.79 on Thursday. The company has a market capitalization of $520.54 million, a PE ratio of 3.71 and a beta of 1.14. Embecta Corp. has a 52-week low of $8.47 and a 52-week high of $15.55. The business’s fifty day moving average is $9.86 and its 200 day moving average is $12.04.

Embecta (NASDAQ:EMBC) last posted its earnings results on Thursday, February 5th. The company reported $0.71 EPS for the quarter, topping the consensus estimate of $0.67 by $0.04. The business had revenue of $261.20 million during the quarter, compared to analysts’ expectations of $258.07 million. Embecta had a negative return on equity of 26.66% and a net margin of 12.92%.The firm’s revenue was down .3% on a year-over-year basis. During the same period in the previous year, the business earned $0.65 earnings per share. Embecta has set its FY 2026 guidance at 2.800-3.00 EPS. On average, sell-side analysts forecast that Embecta Corp. will post 2.85 EPS for the current fiscal year.

Embecta Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, March 17th. Stockholders of record on Friday, February 27th were issued a dividend of $0.15 per share. The ex-dividend date of this dividend was Friday, February 27th. This represents a $0.60 annualized dividend and a dividend yield of 6.8%. Embecta’s payout ratio is presently 25.32%.

Embecta Profile

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.